Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07811869) titled 'A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Chronic Pruritus of Unknown Origin
Intervention:
Drug: Remibrutinib
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: October 6, 2026
Target Sample Size: 180
Countries of Recruitment:
United Sta...